At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,515 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
In Brief
An observational study for Pulmonary Hypertension. Completed, enrolled 3,515 participants across 54 sites.
Detailed Summary
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedAug 2006
Primary CompletionDec 2012
TodayJul 2026
First PostedAug 31, 2006
Enrollment StartMar 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 19.8 years ago